Insight

Breelyn Wilky: Promising outcomes for immune cold sarcomas with BOT/BAL

Breelyn Wilky/X

Jan 30, 2025, 04:40

Breelyn Wilky: Promising outcomes for immune cold sarcomas with BOT/BAL

Breelyn Wilky, Director of Sarcoma Medical Oncology at University of Colorado Anschutz Medical Campus, shared an article she and her colleagues authored on X:

“Very excited to see this in print! Such promising outcomes for immune cold sarcomas with Botensilimab Plus Balstilimab.”

Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas

Authors: Breelyn A. Wilky et al.

Andrea J. Bullock Anthony B. El-Khoueiry Apostolia M Tsimberidou Arun Singh Benny Johnson BOT/BAL Breelyn A. Wilky Brian Henick cancer Chloe Delepine Daruka Mahadevan Dhan Chand Gary K. Schwartz Jonathan C. Trent Joseph E. Grossman Justin Stebbing Manushak Avagyan Mark Agulnik Michael S. Gordon OncoDaily Oncology Robin L. Jones Steven O'Day Wei Wu

Oncologist Near Me - Hagop Kantarjian: A Legend in Leukemia Research and Treatment

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Best of ASCOGI25

Egypt Cancer Society (ECS) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

No recurrences in MSS colorectal cancer with BOT/BAL neoadjuvant immunotherapy: NEST Trial updates from ASCOGI25